Topics

Scientists designed CRISPR to self-destruct tumor cells carrying p53 mutations, a target no drug has ever reached. A Nature paper details the approach for ovarian, pancreatic, and lung cancers.

CRISPR gene editing enters mainstream medicine as Casgevy approval fuels a clinical trial pipeline for cancer, rare diseases, and autoimmune conditions with FDA cutting red tape.